Format

Send to

Choose Destination
See comment in PubMed Commons below
Best Pract Res Clin Rheumatol. 2010 Jun;24(3):387-400. doi: 10.1016/j.berh.2009.12.002.

Evidence-based management of rapidly progressing systemic sclerosis.

Author information

1
UCLA Scleroderma Program, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. dkhanna@mednet.ucla.edu

Abstract

Systemic sclerosis has the highest case-specific mortality of any of the auto-immune rheumatic diseases, as well as causing major morbidity. It is a major clinical challenge and one that has previously provoked substantial nihilism due to the limited therapeutic options available and the perceived lack of evidence for clinical effectiveness of those treatments that are currently in use. However, this situation is changing; there are emerging data supporting efficacy for some treatment approaches for this patient group together with a growing number of exciting potential novel approaches to treatment that are moving into the clinical arena. Some of the recent clinical trials are reviewed and discussed in detail.

PMID:
20534372
PMCID:
PMC2884006
DOI:
10.1016/j.berh.2009.12.002
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center